Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-like tyrosine kinase-3 internal tandem duplication positive acute myeloid leukemia.
作者信息
Gill Harinder, Man Cheuk-Him, Ip Alvin H W, Choi William W L, Chow Howard C H, Kwong Yok-Lam, Leung Anskar Y H
机构信息
Division of Haematology, Medical Oncology and Bone Marrow Transplantation, Department of Medicine, the University of Hong Kong, China.
Department of Pathology, the University of Hong Kong, China.
出版信息
Haematologica. 2015 Jul;100(7):e250-3. doi: 10.3324/haematol.2014.123034. Epub 2015 Mar 27.
Abstract
摘要
相似文献
1
Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-like tyrosine kinase-3 internal tandem duplication positive acute myeloid leukemia.阿扎胞苷作为索拉非尼诱导的Fms样酪氨酸激酶-3内部串联重复阳性急性髓系白血病缓解后的巩固治疗。
Haematologica. 2015 Jul;100(7):e250-3. doi: 10.3324/haematol.2014.123034. Epub 2015 Mar 27.
2
Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission.在首次完全缓解的FLT3-ITD急性髓系白血病患者中进行有或没有索拉非尼维持治疗的造血细胞移植。
Br J Haematol. 2016 Nov;175(3):496-504. doi: 10.1111/bjh.14260. Epub 2016 Jul 19.
3
Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.FLT3-ITD阳性急性髓系白血病的预后：异基因干细胞移植和酪氨酸激酶抑制剂治疗的影响
J Cancer Res Clin Oncol. 2017 Feb;143(2):337-345. doi: 10.1007/s00432-016-2290-5. Epub 2016 Oct 24.
4
Use of sorafenib for post-transplant relapse in FLT3/ITD-positive acute myelogenous leukemia: maturation induction and cytotoxic effect.索拉非尼在FLT3/ITD阳性急性髓性白血病移植后复发中的应用：成熟诱导和细胞毒性作用。
Haematologica. 2014 Nov;99(11):e222-4. doi: 10.3324/haematol.2014.109975. Epub 2014 Jul 11.
5
Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation.索拉非尼治疗的FLT3-ITD阳性急性髓系白血病患者在异基因干细胞移植后复发的长期生存情况。
Eur J Cancer. 2017 Nov;86:233-239. doi: 10.1016/j.ejca.2017.09.016. Epub 2017 Oct 18.
6
High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation.在异基因造血干细胞移植后复发的FLT3-ITD急性髓系白血病中，索拉非尼的血液学缓解率较高。
Eur J Haematol. 2016 Jun;96(6):629-36. doi: 10.1111/ejh.12647. Epub 2015 Sep 21.
7
Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.克立替尼对耐药性 FLT3-ITD 阳性急性髓细胞性白血病模型具有活性。
Blood. 2013 Nov 21;122(22):3607-15. doi: 10.1182/blood-2013-07-513044. Epub 2013 Sep 17.
8
Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.FLT3 抑制剂治疗 FLT3 突变型急性髓系白血病与继发性 FLT3 酪氨酸激酶结构域突变的发生相关。
Cancer. 2014 Jul 15;120(14):2142-9. doi: 10.1002/cncr.28705. Epub 2014 Apr 15.
9
Sorafenib in Relapsed AML With FMS-Like Receptor Tyrosine Kinase-3 Internal Tandem Duplication Mutation.索拉非尼治疗 FMS 样酪氨酸激酶 3 内部串联重复突变复发性急性髓系白血病。
J Natl Compr Canc Netw. 2015 May;13(5):508-14. doi: 10.6004/jnccn.2015.0070.
10
Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.索拉非尼和舒尼替尼序贯治疗 FLT3-ITD 阳性急性髓系白血病时出现多克隆 FLT3 酪氨酸激酶结构域突变。
Clin Cancer Res. 2013 Oct 15;19(20):5758-68. doi: 10.1158/1078-0432.CCR-13-1323. Epub 2013 Aug 22.
引用本文的文献
1
Emerging DNA Methylome Targets in FLT3-ITD-Positive Acute Myeloid Leukemia: Combination Therapy with Clinically Approved FLT3 Inhibitors.FLT3-ITD 阳性急性髓系白血病中新兴的 DNA 甲基化靶点：与临床批准的 FLT3 抑制剂联合治疗。
Curr Treat Options Oncol. 2024 Jun;25(6):719-751. doi: 10.1007/s11864-024-01202-7. Epub 2024 May 2.
2
Overcoming Resistance to FLT3 Inhibitors in the Treatment of -Mutated AML.克服 FLT3 抑制剂在治疗突变型 AML 中的耐药性。
Int J Mol Sci. 2020 Feb 24;21(4):1537. doi: 10.3390/ijms21041537.
3
[Advances in targeted therapy for childhood acute myeloid leukemia].[儿童急性髓系白血病靶向治疗的进展]
Zhongguo Dang Dai Er Ke Za Zhi. 2017 Jul;19(7):832-836. doi: 10.7499/j.issn.1008-8830.2017.07.020.
4
Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy.骨髓增生异常综合征的分子与细胞机制：对靶向治疗的启示
Int J Mol Sci. 2016 Mar 24;17(4):440. doi: 10.3390/ijms17040440.
本文引用的文献
1
Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.每日给予复发或难治性急性髓系白血病患者quizartinib 的 I 期研究，无论 FMS 样酪氨酸激酶 3 内部串联重复状态如何。
J Clin Oncol. 2013 Oct 10;31(29):3681-7. doi: 10.1200/JCO.2013.48.8783. Epub 2013 Sep 3.
2
Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial.索拉非尼联合强化化疗治疗老年急性髓系白血病：一项随机、安慰剂对照试验的结果。
J Clin Oncol. 2013 Sep 1;31(25):3110-8. doi: 10.1200/JCO.2012.46.4990. Epub 2013 Jul 29.
3
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.阿扎胞苷联合索拉非尼治疗伴有 FLT3 内部串联重复突变的急性髓系白血病的 2 期研究。
Blood. 2013 Jun 6;121(23):4655-62. doi: 10.1182/blood-2013-01-480228. Epub 2013 Apr 23.
4
FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia.FLT3 突变在骨髓增生异常综合征和慢性粒单核细胞白血病中的作用。
Am J Hematol. 2013 Jan;88(1):56-9. doi: 10.1002/ajh.23345. Epub 2012 Oct 31.
5
FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia.FLT3 抑制：急性髓系白血病中不断变化的治疗靶点。
Leukemia. 2013 Feb;27(2):260-8. doi: 10.1038/leu.2012.195. Epub 2012 Jul 16.
6
Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia.一项在年轻初诊成人急性髓系白血病患者中进行的与化疗联用的 FLT3 激酶抑制剂米哚妥林的 Ib 期研究。
Leukemia. 2012 Sep;26(9):2061-8. doi: 10.1038/leu.2012.115. Epub 2012 Apr 27.
7
Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.索拉非尼治疗 FLT3-ITD(+) 急性髓系白血病：有利的初始结果和随后无反应的机制与 D835 突变的出现有关。
Blood. 2012 May 31;119(22):5133-43. doi: 10.1182/blood-2011-06-363960. Epub 2012 Feb 24.
8
Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML).阿扎胞苷可增强急性髓系白血病（AML）患者异基因干细胞移植后调节性 T 细胞的扩增。
Blood. 2012 Apr 5;119(14):3361-9. doi: 10.1182/blood-2011-09-377044. Epub 2012 Jan 10.
9
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.口服 Midostaurin（PKC412）、FMS 样酪氨酸激酶 3 受体（FLT3）和多靶点激酶抑制剂的 IIB 期临床试验，用于治疗伴有野生型或突变型 FLT3 的急性髓系白血病和高危骨髓增生异常综合征患者。
J Clin Oncol. 2010 Oct 1;28(28):4339-45. doi: 10.1200/JCO.2010.28.9678. Epub 2010 Aug 23.
10
Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.异基因造血干细胞移植后低剂量阿扎胞苷维持治疗复发性急性髓系白血病或骨髓增生异常综合征：剂量和方案发现研究。
Cancer. 2010 Dec 1;116(23):5420-31. doi: 10.1002/cncr.25500. Epub 2010 Jul 29.
Zotero 插件